ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.55
1.45%
US Tech 100
20,144.80
0.09%
S&P 500
5,948.71
0.53%
US Dollar vs CAD
1.39734
-0.05%
Bitcoin
98,795.59
0.29%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. UroGen Pharma Ltd (URGN) Share Price

UroGen Pharma Ltd

UroGen Pharma Ltd (URGN)

NASDAQ
11.55
0.10
(0.87%)
Closed November 21 3:00PM
Delayed by 15 minutes
11.55
-0.03
(-0.26%)
After Hours: 5:55PM
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

Key stats and details

Current Price
11.55
Bid
11.25
Ask
13.09
Volume
549,662
11.31 Day's Range 11.82
10.6001 52 Week Range 20.70
Market Cap
487.403M
Previous Close
11.45
Open
11.53
Last Trade
85602
@
11.55
(average)
Last Trade Time
Financial Volume
US$ 6,391,455
VWAP
11.628
Average Volume (3m)
591,124
Shares Outstanding
42,199,414
Dividend Yield
-
PE Ratio
-4.78
Earnings Per Share (EPS)
-2.42
Revenue
82.71M
Net Profit
-102.24M

About UroGen Pharma Ltd

UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment opt... UroGen Pharma Ltd is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.urogen.com
Headquarters
Ra'anana, Center, Isr
Founded
-
UroGen Pharma Ltd is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker URGN. The last closing price for UroGen Pharma was US$11.45. Over the last year, UroGen Pharma shares have traded in a share price range of US$ 10.6001 to US$ 20.70.

UroGen Pharma currently has 42,199,414 shares outstanding. The market capitalization of UroGen Pharma is US$483.18 million. UroGen Pharma has a price to earnings ratio (PE ratio) of -4.78.

Ask ADVFN Intelligence (AI)

URGN Latest News

More News

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

November 18 2024
Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

November 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

November 06 2024
Edgar (US Regulatory)

UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025

New Drug Application for UGN-102 accepted by US FDA; PDUFA target action date set for June 13, 2025 JELMYTO® achieved net product sales of $25.2 million in Q3 2024, compared to $20.9 million in...

November 06 2024
Business Wire

UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference

Fireside Chat on November 12, 2024 at 3:00 PM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and...

November 05 2024
Business Wire

UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024

Conference Call and Webcast Scheduled for Wednesday, November 6, 2024, at 10:00AM ET UroGen Pharma Ltd. (Nasdaq:URGN), a biotech company dedicated to developing and commercializing innovative...

October 30 2024
Business Wire

ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC

The Kaplan-Meier Estimate of Duration of Response at 12 Months in Patients Who Achieved a Complete Response at Three Months was 82.3% Patients Receiving UGN-102 had a 79.6% Complete Response...

October 28 2024
Business Wire

UroGen Announces FDA Acceptance of its New Drug Application for UGN-102

PDUFA goal date set for June 13, 2025 UGN-102 would be the first FDA-approved medicine for LG-IR-NMIBC, if approved UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing...

October 15 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

October 09 2024
Edgar (US Regulatory)

Form 3 - Initial statement of beneficial ownership of securities

October 09 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.54-4.4665012406912.0912.3410.6251025711.27787047CS
4-0.58-4.7815333882912.1313.3310.6246964412.04794167CS
12-2.69-18.890449438214.2414.5710.6259112412.61052574CS
26-1.32-10.256410256412.8720.710.6262377314.57823045CS
52-0.74-6.021155410912.2920.710.600147479614.83561457CS
156-0.55-4.5454545454512.124.134.8529475714.0505619CS
260-17.69-60.499316005529.2435.214.8524270716.2152725CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
WORXSCWorx Corporation
US$ 2.12
(116.33%)
144.38M
CRNCCerence Inc
US$ 5.83
(106.74%)
77.55M
PROCProcaps Group SA
US$ 1.10
(92.48%)
2.58M
IBGInnovation Beverage Group Limited
US$ 1.19
(50.40%)
12.97M
ARQQArqit Quantum Inc
US$ 10.7599
(46.59%)
900.38k
SKKSKK Holdings Limited
US$ 1.01
(-77.85%)
40.45M
TMTCTMT Acquisition Corporation
US$ 2.20
(-65.84%)
530.14k
WCTWellchange Holdings Company Limited
US$ 1.2596
(-62.06%)
2.34M
TMTCUTMT Acquisition Corporation
US$ 2.89
(-56.74%)
14.07k
GLXGGalaxy Payroll Group Ltd
US$ 1.77
(-54.73%)
2.45M
CDTConduit Pharmaceuticals Inc
US$ 0.1048
(13.54%)
579M
NVDANVIDIA Corporation
US$ 146.67
(0.53%)
401.66M
ELABElevai Labs Inc
US$ 0.020072
(-6.21%)
256.24M
AKTSAkoustis Technologies Inc
US$ 0.1022
(17.34%)
211.19M
MARAMARA Holdings Inc
US$ 24.19
(6.89%)
166.43M

Discussion

View Full Feed
hardlesson hardlesson 2 minutes ago
I'm going for comfortably retired, and not consumed by hatred and vengeance.

Corruption exists in the OTC, and all stock markets, the Nasdaq, the TSX, the whole thing is rife with corruption. It could also be said that many private companies get sold, and pad the palm of the Seller, w
HIRU
Doc logic Doc logic 3 minutes ago
The Danish Dude,

L was originally called DCVax-Brain and there was a brief time it was mentioned as DCVax-Lung which was supposedly a miscue. Might need to follow all INDs to match anything depending on how an IND might be required to change. Best wishes.
NWBO
zab zab 3 minutes ago
You always dismiss the last 16 months, you remember the pandemic.  1.3 million Americans died,  10s of millions out of work, the economy at a screeching halt. Trump played golf,  billed the taxpayers,  and was batshit crazy. 
crescentmotor crescentmotor 4 minutes ago
SAVA's OL results were manipulated and, in total, appeared not effective.

In reality, the blinded CMS withdrawal portion of the study showed noticeable hints of disease modification. Over the full eighteen months of the study, the reported data showed the mild patients on Simufilam
AVXL
havnagoodtime havnagoodtime 4 minutes ago
Dude, get help -- seriously -- ASAP.
DPLS
farml1234 farml1234 4 minutes ago
you people are full of it , you short a stock to BK you do not have a buy to cover so the transaction is not completed .

You people are either all rookies or paid bashers for the big boys

jmho
ERHE
Risk Risk 5 minutes ago
That's a huge increase what the heck is going on? Why so much of dilution?? This is ridiculous 
AFFU
nowwhat2 nowwhat2 5 minutes ago
Again, I must say ; You guys have the most boringest kick-offs in the sports industry......
stark12 stark12 6 minutes ago
Scroll down to see we are mentioned under Bonus stocks to keep an eye on:
https://finance.yahoo.com/news/2-stocks-buy-china-tightens-000000898.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAMz9xW3e1_n90YajOb7wLBlNMHVH48y-CtL5gVVBdstQnNqQdGLb1qRMvG2eMn5A
NB
littlejohn littlejohn 6 minutes ago
Supercluster computers need SuperMicro liquid cooling

solutions...

https://finance.yahoo.com/news/supermicros-liquid-cooled-superclusters-ai-170000406.html

so we watch...LJ
SMCI
Not likely Not likely 6 minutes ago
That’s how cults work.


As always, nice work brother.
SPZI
MiamiGent MiamiGent 7 minutes ago
I see what you are saying though, Bull

That if DOJ passed on it, it must be a pretty weak case, something Gaetz could beat.

Well, I guess it depends on the amount of personal mortification one can take, lol

Of course, the elegant solution would be Desanti
PickStocks PickStocks 7 minutes ago
We knew Doreen was still in this mess.....Cactus will post how he is great friends and how he is the know......the way  you will be right is when a distribution happens......
COOP
monentum2play monentum2play 7 minutes ago
a $19 million deal, hedge fund billionaire Ken Griffin has sold two of his four units at luxury Chicago high-rise condominium No. 9 Walton, the Wall Street Journal reports. The sale marks a 44% loss for the Citadel founder, who paid over $34 million for the penthouse residences in 2017.
This
NWBO
LakeshoreLeo1953 LakeshoreLeo1953 8 minutes ago
As was/is Harald Hampel.
AVXL
LakeshoreLeo1953 LakeshoreLeo1953 8 minutes ago
As was/is Harald Hampel.
AVXL
Kool Aid Man Kool Aid Man 8 minutes ago
Archived--9/23/2023--JP Energy Group's mission--"Converting harmful waste into valuable & essential resources." Every page showed stock photos of mountains of plastics and trash along with OPV's (other people's videos) of recycling facilities he didn't own. His scam was to save the planet by conver
SPZI
janice shell janice shell 8 minutes ago
Looks like a possible runoff or recount in Penn for a senate seat.

A recount. It was mandatory; the race was very close.
955 955 8 minutes ago
SEC Chair Gensler Says He’ll Resign on Inauguration Day

https://www.barrons.com/articles/sec-chair-gensler-resign-inaguration-day-7eb9b95a?siteid=yhoof2

Another GS swamp rat gone.

https://investorshub.advfn.com/uimage/uploads/2018/1/15/jzpfgGS.001.jpeg
powerbattles powerbattles 8 minutes ago
This isn’t a discussion. As a subscriber, I am simply sharing my opinion to help improve iHub’s social platform. Whether iHub decides to make changes is entirely up to them. I have no intention of debating or engaging in a discussion.

Your Recent History

NASDAQ
URGN
UroGen Pharma
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved